Meningitis b vaccine booster shows promise in kids
NCT ID NCT01621945
First seen Jun 07, 2026 · Last updated Jun 20, 2026 · Updated 1 time
Summary
This study tested whether a fourth dose of the MenBVac vaccine boosts protection against meningitis B in children. Researchers measured immune responses in 120 children before and after the booster. The goal was to see if the vaccine maintains protective antibody levels over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEISSERIA MENINGITIDIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Maison Du Département
Neufchâtel-en-Bray, 76270, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MenBVac vaccine
What this could lead to
If successful, this could confirm that a fourth dose of MenBVac provides lasting protection against meningitis B in children.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all children or other meningitis strains. The vaccine may not provide long-term immunity for everyone.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.